MedOnect
Using AI and Radio Waves to Defeat Cancer

Cancer constitutes one of the predominant causes of mortality across the globe, with millions of individuals receiving diagnoses annually. As researchers persist in discovering novel treatments and enhancing the efficacy of existing methods to combat this lethal illness, the demand for groundbreaking biotechnologies and immunotherapies is escalating.

MedOnect epitomizes the vanguard of this transformative movement, employing the prodigious potential of immunotherapies and biotechnologies to vanquish cancer. The corporation develops complex medical apparatuses that can mitigate the repercussions of cancer and preserve innumerable lives.

“Our mission is to use cutting-edge artificial intelligence and blockchain technology to revolutionize healthcare science in immunology,” says Dr. Ziad George, Executive Director of MedOnect, Inc.

MedOnect’s innovative AI system employs ensemble learning to create a non-invasive medical product capable of effectively illuminating blood cells and removing cancerous tumors with up to 90 percent efficiency. These results have been substantiated through comprehensive studies and clinical trials.

MedOnect is working to revolutionize cancer detection with its groundbreaking technology that combines radio signals and AI. The company has overcome the challenge of acquiring CT scan datasets from smaller healthcare establishments by using its AI learning system to gather, adjust, and analyze the data.

Currently, MedOnect is collaborating with various partners to improve its AI application. Once the platform is completed, they will submit the results to the FDA for approval before making the product available commercially.

In February 2023, MedOnect conducted a clinical trial using mice to use a sample classifier system based on advanced AI methodologies to enhance the efficacy of low-frequency therapy and reduce the risk of tumor recurrence. A different subset of training data was selected to ensure a higher degree of variability in training the predictive model using radio frequencies of up to 27.12MHz for treatment.

In this experiment, machine learning algorithms were used to measure the uncertainty of space statistical predictors, which proved to be a reliable predictor for accurately targeting tumor cells. The mice’s tumor size was reduced by 90 percent by week four. The results of this experiment revealed that low-frequency electric waves could be used to target and isolate cancer cells and halt their growth.

Our mission is to use cutting-edge artificial intelligence and blockchain technology to revolutionize healthcare science in immunology

MedOnect’s primary focus is on patients in the third and fourth stages of cancer. They aim to provide a comprehensive solution that complements and surpasses other treatments. They will implement a strong marketing strategy to reach more people to achieve this.

MedOnect is dedicated to developing a safe, efficient, non-invasive cancer solution. This will enable cancer patients to avoid the hassle and discomfort of frequent trips to the oncologist and enjoy the convenience of receiving cancer treatment at their own homes.

There is still much work to be done in the fight against cancer, but MedOnect is committed to using technology to make a significant difference in people’s lives.